New mRNA-based flu shot cuts confirmed illness ~27% vs standard; FDA decision expected by Aug. 5.
WHO:Researchers and the FDA; trial participants across age groups
WHAT:An experimental mRNA flu vaccine reduced confirmed flu illness by about 27% versus standard-dose shots; protection held across groups and strains.
WHEN:May 11, 2026 at 2:47 PM ET
WHERE:Florida
WHY:The mRNA technology behind COVID-19 vaccines is being tested to improve annual flu protection.
Reporting from 2 identified publishers across this event arc.
